| 包装: | 1mg |
| 市场价: | 10800元 |
| 产品描述 | Ibalizumab (TMB-355) is a humanised IgG4 monoclonal antibody that prevents HIV cell entry by binding to CD4 receptor. Ibalizumab has the potential for HIV-1 infection research[1]. [1]. Anthony Markham. Ibalizumab: First Global Approval. Drugs. 2018 May;78(7):781-785. |
m.cnreagent.com